Fundraising Overview - The company has been approved by the China Securities Regulatory Commission to issue no more than 64,299,200 new shares, of which 31,420,573 shares were actually issued at a price confirmed on September 5, 2022 [1] - The funds raised are managed in accordance with regulatory guidelines and the company's internal management system, with specific accounts opened at various banks for the purpose of fund storage and management [1][2] Fund Usage and Account Status - The company has established special accounts for the raised funds at several banks, including China Construction Bank and Minsheng Bank, for projects such as the production of inactivated vaccines and the expansion of biological product workshops [2] - As of the announcement date, the status of the fundraising accounts is active, with specific projects linked to each account [2] Project Completion and Fund Reallocation - The company has concluded certain fundraising projects, specifically the "inactivated vaccine production project" and the "product quality inspection workshop project," and has decided to permanently allocate the remaining funds to working capital [3] - Following the completion of these projects, the corresponding fundraising accounts will be closed, and the related storage agreements will be terminated [3]

关于部分募集资金专户销户完成的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、募集资金基本情况 根据中国证券监督管理委员会《关于核准普莱柯生物工程股份有限公司非公 开发行股票的批复》（证监许可〔2022〕1251 号），普莱柯生物工程股份有限 公司（以下简称"公司"）获核准非公开发行不超过 64,299,200 股新股。公司实 际向发行对象非公开发行人民币普通股（A 股）股票 31,420,573 股，发行价格 28.58 元 / 股 ， 募 集 资 金 总 额 为 897,999,976.34 元 ， 扣 除 不 含 税 发 行 费 用 12,179,453.12 元，募集资金净额为人民币 885,820,523.22 元。上述资金于 2022 年 9 月 5 日全部到位，已经立信会计师事务所（特殊普通合伙）审验，并出具信 会师报字〔2022〕第 ZA15752 号《验资报告》。 二、募集资金存放与管理情况 为规范募集资金的管理和使用，保护投资者合法权益，公司依照《上市公司 监管指引第 2 号——上市公司募集资金管 ...

Core Viewpoint - The animal vaccine sector has shown a significant increase, with a 4.00% rise, ranking third among concept sectors, driven by notable gains in several stocks [1][2]. Group 1: Sector Performance - As of May 20, the animal vaccine concept increased by 4.00%, with 19 stocks rising, including *ST Xianfeng, which hit the daily limit, and others like Kexing Pharmaceutical, Ruipu Biological, and Kanghua Biological, which rose by 15.56%, 8.41%, and 6.70% respectively [1][2]. - The animal vaccine sector was among the top-performing sectors, alongside cultivated diamonds and pet economy, which rose by 4.10% and 4.08% respectively [2]. Group 2: Capital Inflow - The animal vaccine sector saw a net inflow of 67 million yuan, with 13 stocks receiving net inflows, and 6 stocks attracting over 10 million yuan in net inflows [2]. - Jinhe Biological led the net inflow with 36.88 million yuan, followed by Kexing Pharmaceutical, Dabeinong, and Plk, which received net inflows of 15.38 million yuan, 13.79 million yuan, and 13.60 million yuan respectively [2][3]. Group 3: Capital Flow Ratios - Stocks such as *ST Xianfeng, Kexing Pharmaceutical, and KQ Biotech had the highest net inflow ratios, at 14.17%, 6.56%, and 5.52% respectively [3]. - The top stocks in terms of capital inflow included Jinhe Biological with a turnover rate of 18.22% and a daily increase of 4.40%, and Kexing Pharmaceutical with a turnover rate of 3.46% and a daily increase of 15.56% [3][4].

Meeting Overview - The shareholders' meeting of Pulaike Biological Engineering Co., Ltd. was held on May 16, 2025, at the company's conference room in Luoyang, Henan Province [1] - The meeting was attended by shareholders representing 37.6494% of the total shares [1] - The meeting was conducted in accordance with the Company Law and the company's articles of association, with a combination of on-site and online voting [1] Voting Results - All proposed resolutions were approved by the shareholders [2][3] - The voting results for the A-shares showed a high approval rate, with the following key votes: - 128,331,003 votes in favor (99.6894%) for the first resolution [1] - 128,313,003 votes in favor (99.6755%) for the second resolution [1] - 128,310,603 votes in favor (99.6736%) for the third resolution [1] - 128,298,003 votes in favor (99.6638%) for the fourth resolution [1] - 128,314,403 votes in favor (99.6765%) for the fifth resolution [1] Major Proposals - The meeting included significant proposals such as: - The reappointment of the accounting firm for 2024 [4] - The use of idle funds for cash management [4] - The extension of certain fundraising projects [4] - The voting results for these proposals also reflected strong shareholder support, with approval rates exceeding 99% for most resolutions [2][3] Legal Compliance - The meeting was witnessed by lawyers from Beijing Deheng Law Firm, confirming that the procedures and results complied with relevant laws and regulations [5]

重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 证券代码：603566 证券简称：普莱柯 公告编号：2025-022 普莱柯生物工程股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 (一)股东大会召开的时间：2025 年 5 月 16 日 (二)股东大会召开的地点：河南省洛阳市洛龙区政和路 15 号公司二楼会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 145 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 128,730,723 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 37.6494 | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 会议由公司董事会召集，由董事长张许科先生主持，本次会议以现场投票与 网络投票相结合的方式召开，北京德恒律师事务所律师出席了现场会议并见证。 ...

北京德恒律师事务所 关于普莱柯生物工程股份有限公司 2024 年年度股东大会的 法律意见 北京德恒律师事务所 DeHeng Law Offices 北京市西城区金融街 19 号富凯大厦 B 座 12 层 电话:010-52682888 传真:010-52682999 邮编:100033 北京德恒律师事务所 关于普莱柯生物工程股份有限公司 2024 年年度股东大会的法律意见 北京德恒律师事务所 关于普莱柯生物工程股份有限公司 2024 年年度股东大会的 法律意见 德恒 01G20240892-01 号 本法律意见仅供普莱柯本次股东大会相关事项的合法性之目的使用. 不得用 作任何其他目的。 本所律师根据《公司法》《证券法》《上市公司股东会规则》等有关法律、法 规和规范性文件以及《公司章程》,按照律师行业公认的业务标准、道德规范和 勤勉尽责的精神,对普莱柯所提供的相关文件和有关事实进行了核查和验证,现 出具法律意见如下: 一、本次股东大会的召集、召开程序 2025 年 4 月 24 目, 公司第五届董事会第十八次会议审议通过《关于召开 2024 年年度股东大会的议案》。2025年 4 月 25 日，公司在指定信息披 ...

证券代码：603566 证券简称：普莱柯 公告编号：2025-021 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为进一步加强与投资者的互动交流，普莱柯生物工程股份有限公司（以下简 称"公司"）定于 2025 年 5 月 22 日（周四）15:25-16:55 参加在全景网举办的 河南辖区上市公司 2025 年投资者网上集体接待日活动，本次活动将采用网络远 程的方式举行，投资者可登陆"全景•路演天下"（http://rs.p5w.net）参与本次互 动交流。 出席本次网上集体接待日活动的人员有：公司董事兼董事会秘书赵锐先生、 证券事务代表田晓龙先生（如有特殊情况，参会人员将可能进行调整），欢迎广 大投资者积极参与。 普莱柯生物工程股份有限公司 关于参加河南辖区上市公司 2025 年投资者网上集体接待日 活动的公告 特此公告 普莱柯生物工程股份有限公司 董 事 会 2025 年 5 月 15 日 ...

公司研究 证 券 研 究 报 告 普莱柯（603566）2024 年报&2025 年一季报点评 推荐（下调） 畜禽主业经营改善，费控出色，宠物业务表 现亮眼 事项： ❖ 公司发布 2024 年报&25 年一季报：24 年实现营收 10.43 亿，同比下降 16.77%， 归母净利 9281 万元，同比下降 46.82%，扣非后归母净利 8050 万元，同比下 降 47.72%。25 年一季度实现营收 2.79 亿，同比增长 18.32%，归母净利 5291 万元，同比增长 93.75%，扣非后归母净利 4890 万元，同比增长 84.27%。 评论： 电话：021-20572579 邮箱：chenpeng1@hcyjs.com 执业编号：S0360521080002 公司基本数据 [ReportFinancialIndex] 主要财务指标 | | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业总收入(百万) | 1,043 | 1,257 | 1,462 | 1,656 | | 同比增速(%) | -16.8% | 20 ...

Investment Rating - The report adjusts the investment rating to "Recommendation" for the company, with a target price of 15.3 CNY based on a projected 30 times PE for 2025 [1][7]. Core Views - The company's main business is gradually recovering, with significant performance in the pet business. The report predicts a net profit of 177 million CNY for 2025 and 211 million CNY for 2026, with an EPS of 0.51 CNY and 0.61 CNY respectively [1][7]. Financial Performance Summary - For 2024, the company achieved a total revenue of 1,043 million CNY, a year-on-year decrease of 16.77%, and a net profit attributable to the parent company of 93 million CNY, down 46.82%. In Q1 2025, revenue reached 279 million CNY, up 18.32%, with a net profit of 53 million CNY, up 93.75% [1][3]. - The financial indicators forecast total revenue growth of 20.6% in 2025, 16.3% in 2026, and 13.3% in 2027. The net profit is expected to grow by 91.2% in 2025 and 19.1% in 2026 [3][8]. Business Segment Performance - The report highlights that the pig vaccine revenue for 2024 was 336 million CNY, down 22.58% year-on-year, while poultry vaccine revenue was 429 million CNY, up 3.31%. The pet business showed remarkable growth, with total revenue of 46.21 million CNY, up 125.16% [1][7]. - In Q1 2025, the pig vaccine revenue was 66.19 million CNY, down 11.64%, while poultry vaccine revenue increased by 33.80% to 123 million CNY. The pet business continued to perform well, with total revenue of 15.13 million CNY, up 90.58% [1][7]. Cost Control and Profitability - The company demonstrated effective cost control in Q1 2025, with a net profit margin of 18.99%, an increase of 7.39 percentage points year-on-year. The overall gross margin for 2024 was 61.09%, remaining stable despite pressures on pig vaccine margins [1][7]. Research and Innovation - The company continues to invest in research and development, enhancing its product matrix with new vaccines and medications. Recent approvals for important products are expected to open new market opportunities [1][7].

Core Viewpoint - The company reported a decline in revenue and net profit for 2024, but showed growth in Q1 2025, particularly in the pet business, indicating a potential recovery and diversification strategy [1][2]. Financial Performance - For 2024, the company achieved revenue of 1.043 billion, a year-on-year decrease of 16.77%, and a net profit of 92.81 million, down 46.82% [1]. - In Q1 2025, revenue reached 279 million, a year-on-year increase of 18.32%, with a net profit of 52.91 million, up 93.75% [1]. Segment Analysis - In 2024, revenue from pig vaccines was 336 million, down 22.58%, while poultry vaccines generated 429 million, up 3.31% [2]. - The pet business showed significant growth, with total revenue of 46.21 million in 2024, up 125.16%, driven by strong performance in pet healthcare products [2]. Cost Management - The company maintained a gross margin of 61.09% in 2024, with a slight increase year-on-year, while Q1 2025 saw a gross margin of 59.71%, reflecting effective cost control despite challenges in the pig vaccine segment [3]. - In Q1 2025, the company reported a net profit margin of 18.99%, an increase of 7.39 percentage points year-on-year, indicating improved profitability [3]. R&D and Innovation - The company has been focusing on R&D, obtaining new veterinary drug certificates for several important products, which may help counteract industry competition [4]. - Ongoing product development includes vaccines for various diseases, positioning the company to enhance its market presence and support the livestock sector [4]. Investment Outlook - The company is expected to gradually recover in its core business while the pet segment continues to grow, with projected net profits of 177 million in 2025 and 211 million in 2026 [4].